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BIOLOGICAL EVALUATION OF AN ANTIBIOTIC
DC-81–INDOLE CONJUGATE AGENT IN HUMAN
MELANOMA CELL LINES
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Pyrrolo[2, 1-c][1, 4]benzodiazepines (PBDs) are potent inhibitors of nucleic acid synthesis
because of their ability to recognize and bind to specific sequences of DNA and form a labile
covalent adduct. DC-81, an antitumor antibiotic produced by Streptomyces species, is a PBD.
We combined DC-81 and an indole carboxylate moiety to synthesize a hybrid designed to
have much higher sequence selectivity in DNA interactivity. In this paper, the cytotoxic
potency of the hybrid in human melanoma cell lines was studied. XTT assay demonstrated
that the DC-81–indole conjugate possessed cytotoxicity against human melanoma cell lines.
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Many compounds have been discovered that bind to
and interact with the B-form of DNA and can inhibit
nucleic acid synthesis and block DNA transcription.
Pyrrolo[2, 1-c][1, 4]benzodiazepines (PBDs) are a group
of potent, naturally occurring antitumor antibiotics
produced by Streptomyces species [1]. The cytotoxic
and antitumor effects of these compounds are be-
lieved to arise from the modification of DNA, which
leads to the inhibition of nucleic acid synthesis and the
production of excision-dependent single- and double-
strand breaks in cellular DNA [2, 3]. These antibiotics
have been proposed to covalently bond to N2 of
guanine to form a neutral minor groove adduct (Figure
1) [4–7]. Anthromycin [8, 9], tomaymycin [10, 11], and
DC-81 [12] are the best-known examples of PBDs. We
have previously reported a very short (6 steps) and
efficient synthesis of DC-81 [13] with an overall yield
of about 35% (67% yield based on recovered starting
material at the fifth step). The reaction can be carried
out on a much larger scale (10 g) than previously
reported syntheses. Furthermore, in the first three
steps, the products are easily recrystallized and pure
enough for subsequent reactions.
Although PBDs have high antitumor activity, they
are cardiotoxic, which has precluded their continued
clinical application [14]. Therefore, hybrid compounds
with active moieties of known antitumor and antiviral
agents are being designed and synthesized to provide
highly sequence-selective DNA-interactive properties
and antitumor activity [15]. Thurston et al reported a
PBD-ethylene diaminetetraacetic acid (EDTA) conju-
gate that covalently binds to DNA at 5’-PuGPu (Pu =
purine, G = guanine) sequences leading to site-specific
cleavage [16]. Because the PBD-EDTA hybrid is GC-
specific, we designed and synthesized hybrid 3 (Figure
2) from DC-81 (1) coupled with an indole carboxylate
moiety (2). DC-81 and indole carboxylate are com-
monly used as medicinal compounds, e.g. as antimi-
totic drugs [17–19]. We expected that hybrid 3 would
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recognize more DNA base pairs and bind sequence-
selectively to the macromolecule.
Melanoma is a rapidly proliferating and highly
metastatic tumor that is resistant to radio- and
chemotherapy. Melanoma provides a classic example
of multistage carcinogenesis, showing well-defined
stages of progression with distinct clinical, biologic,
and histologic characteristics [20].
In the present study, we evaluated the cytotoxicity
of the DC-81–indole conjugate (3), DC-81 (1), and
indole carboxylate (2), either alone or a combination of
1 and 2, by determining the inhibition of cell growth in
various human melanoma cell lines (A2058, A375,
RPMI7951, and Hs695T) in culture. The aim of our
study was to evaluate whether hybrid 3 had more
antitumor activity than DC-81 (1) and indole carboxy-
late 2, either alone or combination.
MATERIALS AND METHODS
Dulbecco’s modified Eagle medium (DMEM), fetal
calf serum (FCS), penicillin/streptomycin (100 U/ml
and 100 µg/ml), Dulbecco’s minimal essential me-
dium (MEM), non-essential amino acids, sodium
pyruvate, Dulbecco’s phosphate buffered saline (PBS),
trypsin-EDTA, and dimethyl sulfoxide (DMSO) were
obtained from Gibco BRL (Gaithersburg, MD, USA).
The XTT assay kit was purchased from Promega
(Madison WI, USA).
Human melanoma cell lines and cell cul-
ture
Four human melanoma cell lines, A2058, A375, Hs695T
and RPMI7951, were purchased from American Type
Culture Collection (Manassas, VA, USA). The cell lines
Figure 2. Proposed reaction of DC-81 (1) with the indole carboxylate moiety 2 to form hybrid 3.
Figure 1. Possible mechanism of the formation of the pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD)-DNA adduct.
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were maintained in culture medium (MEM: A2058
and A375; MEM with 0.1 mM non-essential amino
acids, 1.0 mM sodium pyruvate: Hs695T and
RPMI7951) supplemented with 10% FCS, 100 U/ml
penicillin G, and 100 µg/ml streptomycin sulfate.
Melanoma cells were passaged at confluence after
treatment with 5 mM EDTA (Gibco BRL) and incu-
bated at 37°C in a humidified atmosphere containing
5% carbon dioxide. Following trypsinization and cell
counting, cells in 100 µl culture medium were seeded
into 96-well microtiter plates (2 x 103 cells/well).
Cytotoxicity
Antitumor compounds were dissolved in DMSO at a
final concentration of 1 mg/ml and stored at 4°C.
After the cells adhered to the plate, the supernatant
was aspirated and 100 µl of media containing various
concentrations of different test agents were added to
the wells for 24-hour incubation. Each experiment was
repeated three times. After incubation, the XTT assay
was performed as described below. Inhibiting concen-
tration (IC) was determined by plotting compound
concentration versus cell viability. The mean IC50 value
was calculated for each cell line.
XTT assay
We determined the relationship between the number
of cells and formazan production. XTT solution (20 µl)
was added to each well. Following 2 hours’ incubation,
absorbance at 490 nm was measured in an enzyme-
linked immunosorbent assay (ELISA) reader to deter-
mine proliferation by quantifying cellular metabolic
activity. The results were expressed as the optical
density of the control in triplicate cultures [21]. The
unpaired Student’s t-test was used for statistical evalu-
ation of the relationship between the control and
experimental groups; p < 0.05 was considered statisti-
cally significant.
RESULTS
Results are shown in Figures 3 to 6 for A2058, A375,
RPMI7951, and Hs695T, respectively. The cytotoxic
effects were dependent on drug concentration. Hy-
brid 3 was the most potent inhibitor of A2058, A375,
and RPMI7951. However, all compounds tested had
equal potency against Hs695T cells. The Table shows
the IC50 values; treatment with DC-81 (1) or a combina-
Figure 3. Dose-response curves for compounds tested against A2058 cells (2 x 103 cells/well, 2-day culture, 1-day treatment, 2-hour
incubation with XTT). Results are expressed as mean ± standard deviation.
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Figure 4. Dose–response curves for compounds tested against A375 cells (same experimental conditions as in Figure 3).
Figure 5. Dose-response curves for compounds tested against RPMI7951 cells (same experimental conditions as in Figure 3).
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tion of 1 and 2 gave very similar results on all cell lines
except Hs695T.
DISCUSSION
DNA is a target for many antitumor drugs currently
used in the clinic. However, there are only a few DNA-
interactive agents that bind to DNA with high se-
quence selectivity. Selectivity is generally thought to
favor the targeting of rapidly growing tumor cells, so
Figure 6. Dose-response curves for tested compounds against Hs695T cells (same experimental conditions as in Figure 3).
the development of low molecular weight molecules
with highly sequence-selective DNA-interactive prop-
erties is of interest. One approach to this involves the
design and synthesis of molecules with predictable
affinity-cleavage properties that might function as
artificial restriction enzymes to inhibit tumor cell pro-
liferation and metastasis. DC-81 (1) exhibits its bio-
logical activity by covalently binding to the N2 of
guanine in the minor groove of DNA, via the
electrophilic carbinolamine functionality at N10-C11.
The (S) configuration at the chiral C11a position pro-
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Table. In vitro cytotoxicity of tested compounds on human melanoma cell lines A2058, A375, RPMI7951, and
Hs695T
IC50 (µM)
Cell line Hybrid 3 Mix (1 plus 2) DC-81 (1) Indole carboxylate (2)
RPMI7951 18.4 36.9 41.5 128.6
Hs695T NC NC NC NC
A2058 17.4 33.5 31.0 294.2
A375 14.1 20.8 18.5 25.7
NC = not calculable. IC50 (50% inhibitory concentration) represents the mean from dose-response curves of three experiments.
DC-81–indole hybrid in human melanoma
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vides the molecules with the necessary right-hand
twist to fit properly within the minor groove of DNA,
spanning three base pairs for 5’-PuGPu sequences. In
this study, we used the XTT assay to evaluate the
cytotoxicity of tested compounds in human melanoma
cell lines. Our results indicated that hybrid 3 was more
effective as an antiproliferative agent than DC-81 (1)
and indole carboxylate (2), sufficient to strongly in-
hibit A2058, A375, and RPMI7951 cell growth. One can
speculate that this was because hybrid 3 recognized
more DNA-binding sites, increasing the stability of
the drug/DNA complex. We will investigate the struc-
ture of the drug/DNA complex using molecular
modeling. It was surprising that hybrid 3 had no
inhibitory effect on Hs695T. Based on our results, we
suggest that hybrid 3 may be a cell-selective antitumor
agent, which encourages us to design more diverse
antitumor DC-81 analogues.
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